![Karine Chorro](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jean-François Floch | M | - |
BioRéalités SAS
![]() BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | 17 Jahre |
Ludovic Clarion | M | - |
Phost’in SAS
![]() Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | 10 Jahre |
Geneviève Blanc | F | 60 |
BioRéalités SAS
![]() BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | - |
Dominique Joubert | M | - |
BioRéalités SAS
![]() BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | 17 Jahre |
Frederic Hollande | M | - |
BioRéalités SAS
![]() BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | 17 Jahre |
Bernard Pau | M | - |
Phost’in SAS
![]() Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | 4 Jahre |
Richard John Meadows | M | - |
Phost’in SAS
![]() Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | 4 Jahre |
Christophe Carniel | M | 58 |
BioRéalités SAS
![]() BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | - |
Pierre Tambourin | M | - |
BioRéalités SAS
![]() BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | - |
Jean-Luc Bernard | M | - |
BioRéalités SAS
![]() BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | - |
Jocelyn Olive | M | - |
BioRéalités SAS
![]() BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | - |
Hitoshi Ono | M | - |
Phost’in SAS
![]() Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | 4 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Frankreich | 12 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Karine Chorro
- Persönliches Netzwerk